Patients should be monitored closely for volume status and electrolyte balance, glycemic control, albuminuria, and estimated glomerular filtration rate (eGFR)
Remember, the right dose for you might be different from someone elses
In a 26-week rat oral toxicity study, AOD-9604 produced dose-dependent changes in serum osteocalcin (a bone-turnover marker) at week 13, with the direction reversing by week 26
The hallmark symptom of acute pancreatitis is severe, persistent abdominal pain , typically described as: Located in the upper abdomen (epigastric or left upper quadrant) Radiating to the back in approximately 50% of cases, often described as a "band-like" distribution Sudden in onset and constant in nature, rather than colicky Worsening after eating , particularly after fatty meals Not relieved by simple analgesia or changes in position Accompanying symptoms frequently include: Nausea and vomiting that may be persistent and severe Fever and tachycardia as systemic inflammatory responses develop Abdominal distension and tenderness on examination Jaundice (in cases associated with gallstones or biliary obstruction) Signs of systemic compromise such as hypotension, confusion, or reduced urine output in severe cases Patients should be specifically counselled that these symptoms differ from the common gastrointestinal side effects of tirzepatide, such as mild nausea, occasional vomiting, or transient abdominal discomfort, which typically occur early in treatment and resolve spontaneously
